2. Search Result
Search Result
Results for "

Wi-38

" in MedChemExpress (MCE) Product Catalog:

51

Inhibitors & Agonists

1

Fluorescent Dyes

5

Peptides

4

Natural
Products

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-N2217
    Rotundic acid

    		Akt mTOR p38 MAPK Apoptosis Phosphatase Interleukin Related NF-κB PI3K Keap1-Nrf2 Heme Oxygenase (HO) Toll-like Receptor (TLR) Reactive Oxygen Species (ROS) Metabolic Disease Inflammation/Immunology Cancer
    Rotundic acid is an orally effective triterpenoid with a Kd value of 51.3 µM for PTP1B. Rotundic acid downregulates the AKT/mTOR pro-survival pathway and modulates the MAPK pathway. Rotundic acid induces cell cycle S-phase arrest, DNA damage and apoptosis; it inhibits migration, invasion, angiogenesis and proliferation of cancer cells. Rotundic acid improves leptin sensitivity, regulates gut microbiota and reduces cellular senescence. Rotundic acid can be used in research related to hepatocellular carcinoma, obesity, aging, acute lung injury and type 2 diabetes .
    Rotundic acid
  • HY-U00447
    PK11000

    		MDM-2/p53 DNA Alkylator/Crosslinker Cancer
    PK11000 is an alkylating agent, and stabilizes the DNA-binding domain of both WT and mutant p53 proteins by covalent cysteine modification without compromising DNA binding. PK11000 has anti-tumor activities .
    PK11000
  • HY-147785
    Pim-1 kinase inhibitor 2
    1 Publications Verification

    		 Pim Caspase Bcl-2 Family Apoptosis Cancer
    Pim-1 kinase inhibitor 2 is a PIM-1 kinase inhibitor with a human IC50 of 0.63 μM. Pim-1 kinase inhibitor 2 exhibits high selectivity for cancer cells over normal cells. Pim-1 kinase inhibitor 2 induces apoptosis, increases active caspase-3 levels, upregulates BAX, downregulates Bcl-2, and elevates the Bax/Bcl-2 ratio. Pim-1 kinase inhibitor 2 suppresses cancer cell proliferation and induces cell cycle arrest. Pim-1 kinase inhibitor 2 can be used for the research of prostate carcinoma, hepatocellular carcinoma, and breast adenocarcinoma .
    Pim-1 kinase inhibitor 2
  • HY-136093B
    Lixumistat
    1 Publications Verification

    IM156 free base; HL156A free base; HL271 free base

    		 Mitochondrial Metabolism AMPK Neurological Disease Inflammation/Immunology
    Lixumistat (IM156 free base) is a potent and orally active AMPK activator and OXPHOS inhibitor. Lixumistat strongly activates AMPK, while it lacks the systemic metabolic regulatory effects of classic metformin, such as hypoglycemic and weight-lowering activities. Lixumistat exhibits significant therapeutic effects on cognitive decline associated with brain aging and pulmonary fibrosis .
    Lixumistat
  • HY-115924
    CDK1-IN-1

    		CDK Cancer
    CDK1-IN-1 is a potent CDK1 inhibitor (CDK1/CycB IC50=161.2 nM) with potential antiproliferative activity and selectivity for cancer tissues. CDK1-IN-1 induces apoptosis in p53 dependent manner through the intrinsic apoptotic pathway. CDK1-IN-1 is a potential targeted antitumor agent .
    CDK1-IN-1
  • HY-147646
    CDK1/Cyc B-IN-1

    		CDK Apoptosis Cancer
    CDK1/Cyc B-IN-1 (Compound 5) is a selective CDK1/Cyc B complex inhibitor with an IC50 of 97 nM. CDK1/Cyc B-IN-1 triggers apoptosis and G2/M cell cycle arrest. CDK1/Cyc B-IN-1 shows broad-spectrum cytotoxic action against cancer cell lines .
    CDK1/Cyc B-IN-1
  • HY-161088
    Anti-aging agent 1

    		Drug Derivative ERK Others
    Anti-aging agent 1 (compound 24) is a derivative of piperlongumine (HY-N2329) (PL). Anti-aging agent 1 exhibits a 50-fold enhancement in senolytic activity against senescent WI-38 fibroblasts compared to PL .
    Anti-aging agent 1
  • HY-170027
    LW1564

    		HIF/HIF Prolyl-Hydroxylase AMPK Cancer
    LW1564 is an inhibitor for HIF-1α with an IC50 of 1.2 µM in HepG2. LW1564 inhibits mitochondrial respiration, reduces ATP production, stimulates HIF-1α degradation, and inhibits proliferation of various cancer cells with GI50 of 0.4-4.6 μM. LW1564 activates AMPK signaling pathway and inhibits lipid synthesis. LW1564 exhibits antitumor in HepG2 xenograft mouse model .
    LW1564
  • HY-N12792
    5,8-Dihydroxy-3',4',6,7-tetramethoxyflavone

    		Others Cancer
    5,8-Dihydroxy-3',4',6,7-tetramethoxyflavone (Compound 8) is a flavonoid with anticancer activity. 5,8-Dihydroxy-3',4',6,7-tetramethoxyflavone can be isolated from Euryops arabicus .
    5,8-Dihydroxy-3',4',6,7-tetramethoxyflavone
  • HY-157404
    Pim-1/2 kinase inhibitor 2

    		Pim Cancer
    Pim-1/2 kinase inhibitor 2 (compound 5b) is a competitive PIM-1 and PIM-2 kinase inhibitor with IC50s of 1.31 μM and 0.67 μM, respectively. Pim-1/2 kinase inhibitor 2 shows in-vitro low cytotoxicity against normal human lung fibroblast Wi-38 cell line and potent in-vitro anticancer activity against myeloid leukaemia (NFS-60), liver (HepG-2), prostate (PC-3), and colon (Caco-2) cancer cell lines .
    Pim-1/2 kinase inhibitor 2
  • HY-N11128
    Solidagonic acid

    		Kinesin Cancer
    Solidagonic acid is an acidic bitter principle that can be found in the root and rhizomes of Solidago altissima L. Solidagonic acid binds HSET/KIFC1, restores growth in HSET-overproducing fission yeast cells and reverts mitotic spindles from monopolar to bipolar morphology. Solidagonic acid can be used for the research of breast adenocarcinoma .
    Solidagonic acid
  • HY-147802
    EGFR-IN-59

    		EGFR Apoptosis Cancer
    EGFR-IN-59 (Compound 8c) is a EGFR inhibitor (IC50=190 nM) and apoptosis inducer. EGFR-IN-59 exhibits cytotoxicity against non-small lung cancer cell lines (A549) and normal lung fibroblasts (WI38) with IC50s of 8.62 and 52.6 µM, respectively. EGFR-IN-59 can be used for the research of various cancers such as non-small cell lung cancer (NSCLC), head and neck cancer, breast cancer and colorectal cancer .
    EGFR-IN-59
  • HY-170483
    Antitumor agent-191

    		HSV HIV Infection Cancer
    Antitumor agent-191 (Compound 7) exhibits antiviral activity against HSV-1 and HIV with EC50 of 0.03 μM and 0.81 μM. Antitumor agent-191 exhibits potential antitumor efficacy, that inhibits cancer cell HepG2, WI-38, Vero and MCF-7, with IC50s of 19.6, 39.3, 18.3 and 28 μM, respectively .
    Antitumor agent-191
  • HY-174320
    SARS-CoV-2-IN-112

    		SARS-CoV Infection
    SARS-CoV-2-IN-112 (Compound 6f) is an orally active and non-peptidic SARS-CoV-2 main protease inhibitor with an IC50 of 6.48 μM. SARS-CoV-2-IN-11 has potent antiviral activity with low cytotoxicity against WI-38 cells (IC50: 53.81 μM). SARS-CoV-2-IN-112 can be used for coronaviruses COVID-19 research .
    SARS-CoV-2-IN-112
  • HY-126311
    4-Hydroxyresveratrol

    3,4,5,4'-Tetrahydroxystibene

    		 MDM-2/p53 Bcl-2 Family Apoptosis Cancer
    4-Hydroxyresveratrol (3,4,5,4'-Tetrahydroxystibene), a Resveratrol (HY-16561) analog, differentially induces pro-apoptotic p53/Bax gene expression. 4-Hydroxyresveratrol induces apoptosis in SV40 virally transformed WI38 cells (WI38VA) cells, but not in WI38 cells. 4-Hydroxyresveratrol significantly induces the expression of p53, GADD45 and Bax genes and concomitantly suppresses the expression of bcl-2 gene in WI38VA .
    4-Hydroxyresveratrol
  • HY-170661
    EGFR-IN-142

    		EGFR Cancer
    EGFR-IN-142 (compound 9a) is an EGFR inhibitor with an IC50 value of 0.08 μM. EGFR-IN-142 shows antiproliferative to MCF-7 (IC50 3.31 µM) and WI-38 (IC50 = 43.99 µM) .
    EGFR-IN-142
  • HY-149407
    Multi-kinase-IN-4

    		VEGFR CDK EGFR Necroptosis Apoptosis Cancer
    Multi-kinase-IN-4 (compound 5d) is multi-targeted kinase inhibitor, including VEGFR2, EGFR, HER2, and CDK2, with IC50 values of 0.33, 0.22, 0.18 and 2.09 μM, respectively. Multi-kinase-IN-4 shows broad-spectrum anti-cancer activities against HepG2, MCF-7, MDA-231, and HeLa cell lines (IC50 = 1.94–7.1 µM), but exhibits lower toxicity in the WI-38 cells (IC50 = 40.85 µM). Multi-kinase-IN-4 induces apoptosis and arrests cell cycle at S phase in HepG2 cells. Multi-kinase-IN-4 has the potential for the research of cancer .
    Multi-kinase-IN-4
  • HY-152758
    Caspase-3/7 activator 3

    		Apoptosis Caspase Cancer
    Caspase-3/7 activator 3 is an effective activator of Caspase-3/7. Caspase-3/7 activator 3 has tumor selectivity, anti-proliferative activity and high Apoptosis-inducing ability .
    Caspase-3/7 activator 3
  • HY-169688
    NA-17

    		MDM-2/p53 Apoptosis Cancer
    NA-17 is a naphthalimide compound with anti-tumor activity and lower toxicity to normal cells like HL-7702 and WI-38. NA-17 exhibits a p53-dependent selective inhibition in various NSCLC cells, inducing the accumulation of active p53 in the mitochondria and nuclei of NSCLC cells. NA-17 can cause cell cycle arrest in the G1 phase, leading to apoptosis and cell death .
    NA-17
  • HY-103289
    MEN 11270

    		Bradykinin Receptor Metabolic Disease Inflammation/Immunology
    MEN 11270, a cyclic decapeptide, is a B2 kinin receptor antagonist. MEN 11270 bound with high-affinity to the B2 kinin receptor constitutively expressed by WI38 human fibroblasts, inhibiting 3H-bradykinin (BK) with a pKi value of 10.3 .
    MEN 11270
  • HY-120356
    T-1101

    TAI-95

    		 Apoptosis NEKs Cancer
    T-1101 (TAI-95) is an orally active inhibitor for mitose regulating highly expressed oncoprotein 1 (Hec1). T-1101 blocks the interaction between Hec1 and NEK2, exhibits cytotoxicity in human liver cancer cells with GI50 of 15-70 nM. T-1101 induces apoptosis in Huh-7. T-1101 exhibits antitumor efficacy in mouse models .
    T-1101
  • HY-173367
    Anticancer agent 271

    		EGFR PI3K mTOR Cancer
    Anticancer agent 271 (compound 5C) has antiproliferative activity against lung (A549), colon (Caco-2) cancer cell lines, and human lung fibroblast (WI38) with an IC50 value of 9.18 μM on A549 cells. Anticancer agent 271 downregulates PI3K and mTOR gene expression that can be used for cancer research .
    Anticancer agent 271
  • HY-175174
    Antiproliferative agent-73

    		Glutaminase Cancer
    Antiproliferative agent-73 (Compound 7) is an antiproliferative agent. Antiproliferative agent-73 significantly inhibits proliferation of human cancer cells with excellent cytotoxicity. Antiproliferative agent-73 has potent anticancer activity with IC50s of 15.20, 18.18, 20.20 and 13.23  μM for HepG2, MCF-7, HCT-116 and WI38 cells, respectively. Antiproliferative agent-73 can be used for cancers research, such as breast, colorectal and liver cancer .
    Antiproliferative agent-73
  • HY-158726
    Complex 3

    		Fluorescent Dye Apoptosis Cancer
    Complex 3 is a fluorescent dithiocarbazate-copper complex with anticancer activity, which localizes to mitochondria. Complex 3 displays excitation/emission maxima of 455-495/535 nm, respectively. Complex 3 inhibits the growth of BxPC-3, AsPC-1, PANC-1, and WI38 pancreatic cancer cells with IC50 values of 0.74, 0.41, 0.62, and 2.06 µM, respectively. Complex 3 induces lipid peroxidation and mitochondrial rupture and shrinkage in AsPC-1 cells. Complex 3 also induces mitochondrial apoptosis and cytokine-cytokine receptor interaction dysfunction in AsPC-1 cells. Complex 3 reduces tumor volume in an AsPC-1 mouse xenograft model .
    Complex 3
  • HY-180546
    CDK2-IN-53

    		CDK Cancer
    CDK2-IN-53 (compound 9) is a CDK2 inhibitor with anticancer activity. CDK2-IN-53 selectively inhibits the proliferation of HCT-116 and MCF-7cells with IC50 values of 13.89 and 7.65 μM, respectively, while showing lower cytotoxicity toward normal lung fibroblast (WI-38) cells (IC50 = 71.24 μM). CDK2-IN-53 can be used for cancer research, such as colon and breast cancer .
    CDK2-IN-53
  • HY-152748
    Caspase-3/7 activator 1

    		Apoptosis Caspase Cancer
    Caspase-3/7 activator 1 is an effective activator of Caspase-3/7. Caspase-3/7 activator 1 has tumor selectivity, anti-proliferative activity and high Apoptosis-inducing ability .
    Caspase-3/7 activator 1
  • HY-172110
    Apoptosis inducer 35

    		EGFR Akt p38 MAPK ERK Apoptosis Cancer
    Apoptosis inducer 35 (Compound 6) is a multi-targeted inhibitor, that reduces the expressions of EGFR, AKT, ERK and P38-MAPKα. Apoptosis inducer 35 inhibits the proliferation of cancer cell A549 and Jurkat, arrests the cell cycle at S phase, and induces apoptosis .
    Apoptosis inducer 35
  • HY-152756
    Caspase-3/7 activator 2

    		Apoptosis Caspase Cancer
    Caspase-3/7 activator 2 is an effective activator of Caspase-3/7. Caspase-3/7 activator 2 has tumor selectivity, anti-proliferative activity and high Apoptosis-inducing ability .
    Caspase-3/7 activator 2
  • HY-172872
    CDK2-IN-45

    		CDK Apoptosis Cancer
    CDK2-IN-45 (Compound 8f) is a CDK2 inhibitor (IC50: 0.64 μM). CDK2-IN-45 inhibits the proliferation of DU-145 and PC-3 cell lines with IC50 of 2.20 μM and 4.17 μM, respectively. CDK2-IN-45 induces G0/G1 cell cycle arrest and apoptosis. CDK2-IN-45 can be used in prostate cancer research .
    CDK2-IN-45
  • HY-118945
    FR191413

    		Prostaglandin Receptor Bradykinin Receptor Cardiovascular Disease Metabolic Disease Inflammation/Immunology
    FR191413 is a selective bradykinin B2 receptor agonist that stimulates prostaglandin E2 production in WI-38 cells and activates BK B2 receptor-mediated pathways such as vasodilation and organ protection. FR191413 competitively binds to [ 3H]-BK in guinea pig ileum (GPI) membranes and CHO cells transfected with the human BK B2 receptor, with IC50 values ​​of 20.0 nM and 2.60 nM, respectively. FR191413 can be used in research related to cardiovascular diseases and diabetes, including hypertension, myocardial hypertrophy, myocardial infarction, arrhythmias, and diabetic nephropathy .
    FR191413
  • HY-144810
    CDK2-IN-8

    		CDK Cancer
    CDK2-IN-8 is a potent CDK2 inhibitor with an IC50 of 1.74 µM. CDK2-IN-8 shows antiproliferative activity. CDK2-IN-8 has the potential for the research of melanoma .
    CDK2-IN-8
  • HY-146218
    MMP-9-IN-5

    		MMP Akt Apoptosis Cancer
    MMP-9-IN-5 is a MMP-9 inhibitor (IC50: 4.49 nM) that forms hydrogen bond with MMP-9. MMP-9-IN-5 also inhibits AKT activity (IC50: 1.34 nM). MMP-9-IN-5 shows cell cytotoxicity and induces cell apoptosis. MMP-9-IN-5 can be used in the research of cancers .
    MMP-9-IN-5
  • HY-146216
    MMP-9-IN-3

    		MMP Akt Apoptosis Cancer
    MMP-9-IN-3 is a MMP-9 inhibitor (IC50: 5.56 nM) that forms hydrogen bond with MMP-9. MMP-9-IN-3 also inhibits AKT activity (IC50: 2.11 nM). MMP-9-IN-3 shows cell cytotoxicity and induces cell apoptosis. MMP-9-IN-3 can be used in the research of cancers .
    MMP-9-IN-3
  • HY-P5838
    Citrullinated LL-37 5cit

    		Bacterial Inflammation/Immunology
    Citrullinated LL-37 5cit is a citrullinated LL-37 (HY-P1222) peptide. The antiviral and antibacterial effects of Citrullinated LL-37 5cit are significantly reduced compared to native LL-37. Citrullinated LL-37 5cit is unable to reduce LPS-mediated release of TNF-α due to a lack of LPS-binding capacity .
    Citrullinated LL-37 5cit
  • HY-P5843
    Citrullinated LL-37 4cit

    		Enterovirus Infection
    Citrullinated LL-37 3cit is a citrullinated LL-37 (HY-P1222) peptide. Citrullinated LL-37 3cit lacks all antiviral activity at 10 μg/mL and retains some activity against HRV at 30 μg/mL. Citrullinated LL-37 3cit reduces the immunomodulatory activity of LL-37. Citrullinated LL-37 3cit shows a moderate loss in the ability to reduce HRV-induced CCL5 secretion .
    Citrullinated LL-37 4cit
  • HY-P5836
    Citrullinated LL-37 1cit

    		Interleukin Related Bacterial Enterovirus Inflammation/Immunology
    Citrullinated LL-37 1cit is a citrullinated LL-37 (HY-P1222) peptide. Citrullinated LL-37 1cit does not alter the antiviral effect of LL-37 toward human rhinovirus. Citrullinated LL-37 1cit shows antibacterial activity toward S. aureus. Citrullinated LL-37 1cit causes a reduction in the levels of IL-8, CCL5, and IL-6 mRNA induced by RV1B .
    Citrullinated LL-37 1cit
  • HY-164320
    Anticancer agent 245

    		Apoptosis Cancer
    Anticancer agent 245 (Compound 115) inhibits proliferation of cancer cell SKOV3, MDA-MB-231 and HCT-116 with IC50 of 0.021, 0.056 and 0.11 μM, respectively. Anticancer agent 245 exhibits antitumor efficacy in mice and good pharmacokinetic characteristics in rat models .
    Anticancer agent 245
  • HY-146217
    MMP-9-IN-4

    		MMP Akt Apoptosis Cancer
    MMP-9-IN-4 is a MMP-9 inhibitor (IC50: 7.46 nM) that has H-π interactions with MMP-9. MMP-9-IN-4 also inhibits AKT activity (IC50: 8.82 nM). MMP-9-IN-4 shows cell cytotoxicity and induces cell apoptosis. MMP-9-IN-4 can be used in the research of cancers .
    MMP-9-IN-4
  • HY-P5837
    Citrullinated LL-37 2cit

    		Interleukin Related Enterovirus Inflammation/Immunology
    Citrullinated LL-37 2cit is a citrullinated LL-37 (HY-P1222) peptide. Citrullinated LL-37 2cit reduces LL-37 activity against HRV at 10 μg/mL and reduces the antibacterial effect of LL-37. Citrullinated LL-37 2cit causes a reduction in the levels of IL-8, CCL5, and IL-6 mRNA induced by RV1B. Citrullinated LL-37 2cit shows a moderate loss in the ability to reduce HRV-induced CCL5 secretion .
    Citrullinated LL-37 2cit
  • HY-170311
    YAP/TEAD-IN-1

    		YAP Cancer
    YAP/TEAD-IN-1 (compound 4) is a potent YAP and TEAD inhibitor. YAP/TEAD-IN-1 shows antioxidant activity. YAP/TEAD-IN-1 shows antiproliferation activity for tumor cells. YAP/TEAD-IN-1 shows little cytotoxic activity for human normal cells .
    YAP/TEAD-IN-1
  • HY-174855
    PI3K/mTOR-IN-17

    		PI3K mTOR Apoptosis Bcl-2 Family MDM-2/p53 Caspase Cancer
    PI3K/mTOR-IN-17 is a dual PI3K and mTOR inhibitor with IC50 values of 1.21 μM (PI3K), and 0.21 μM (mTOR). PI3K/mTOR-IN-17 induces cells caspase-mediated apoptosis by arresting their growth in the G1-phase. PI3K/mTOR-IN-17 upregulates the levels of caspases-3, 7, 8, and 9, p53 expression and Bax/Bcl-2 ratio. PI3K/mTOR-IN-17 suppresses the PI3K/mTOR signaling pathway. PI3K/mTOR-IN-17 can be used for research of cancer, such as non-small cell lung cancer (NSCLC) .
    PI3K/mTOR-IN-17
  • HY-180169
    Photosensitizer-8

    		Photosensitizer Drug Derivative Cancer
    Photosensitizer-8 (Compound 4), 2-anthrol derivative, is an alkaline phosphatase (ALP)-activatable photosensitizer. Photosensitizer-8 undergoes a phosphate ester hydrolysis reaction in the presence of ALP, rapidly converting into the active photosensitizer 2-anthrol. Photosensitizer-8 exhibits cytotoxicity against ALP-overexpressing cancer cells (HeLa, A549, HCT116) after light exposure, with IC50 values of 14.3 μM, 21.6 μM and 17.5 μM, respectively, while showing no significant cytotoxicity against normal lung fibroblasts (WI-38) (IC50 ≥ 30 μM). Photosensitizer-8 can be used in photodynamic therapy research for ALP-overexpression-related cancers .
    Photosensitizer-8
  • HY-163747
    VEGFR-2-IN-47

    		VEGFR Cancer
    VEGFR-2-IN-47 (compound 7g) is a potent VEGFR-2 inhibitor with an IC50 value of 0.072 µM. VEGFR-2-IN-47 can induce G2 / M phase cell cycle arrest, promote apoptosis, and boost immunomodulation by downregulating TNF-α expression and upregulating IL-2 levels in MCF-7 cells. VEGFR-2-IN-47 has the potential to be used for the research of cancer such as breast cancer and liver carcinoma .
    VEGFR-2-IN-47
  • HY-181528
    JAK1/CDK7-IN-1

    		JAK CDK Cancer
    JAK1/CDK7-IN-1 (compound 11) is a JAK1/CDK7 inhibitor and cytotoxic agent.JAK1/CDK7-IN-1 forms a stable, tightly bound complex with JAK1.JAK1/CDK7-IN-1 disrupts cell cycle, induces G2/M phase arrest, and increases Pre-G1 phase cell proportion.JAK1/CDK7-IN-1 induces apoptosis, elevates caspase 1, 3, and 9 levels, and triggers apoptotic and necrotic cell death.JAK1/CDK7-IN-1 can be used for the research of breast cancer, prostate cancer .
    JAK1/CDK7-IN-1
  • HY-183369
    VEGFR/PD-L1-IN-1

    		VEGFR PD-1/PD-L1 Apoptosis Bcl-2 Family Caspase Cancer
    VEGFR/PD-L1-IN-1 is a VEGFR2 and PD-L1 inhibitor, with IC50 values of 0.383 μM and 134.407 pg/mL against VEGFR2 and PD-L1, respectively. VEGFR/PD-L1-IN-1 enhances the secretion of INF-γ, induces G0/G1 cell cycle arrest in cancer cells, and triggers cancer cell apoptosis. VEGFR/PD-L1-IN-1 upregulates the expression of BAX and Caspase-3, and downregulates the expression of Bcl-2. VEGFR/PD-L1-IN-1 can be used in research related to hepatocellular carcinoma, prostate cancer, and colorectal cancer .
    VEGFR/PD-L1-IN-1
  • HY-181726
    BRAFV600E/ABL2-IN-2

    		PERK P-glycoprotein Apoptosis Cancer
    BRAFV600E/ABL2-IN-2 is a dual BRAFV 600E and ABL2 kinase inhibitor, with an IC50 of 0.088 μM against human BRAFV 600E and an IC50 of 0.3 μM against human ABL2. BRAFV600E/ABL2-IN-2 reduces the phosphorylation levels of downstream ERK1/2 and CrkL in melanoma cells. BRAFV600E/ABL2-IN-2 decreases the expression of P-glycoprotein (P-glycoprotein) in melanoma cells. BRAFV600E/ABL2-IN-2 induces G1 cell cycle arrest and apoptosis (Apoptosis) in melanoma cells. BRAFV600E/ABL2-IN-2 is applicable to relevant research on melanoma .
    BRAFV600E/ABL2-IN-2
  • HY-183108
    Anticancer agent 315

    		Thymidylate Synthase Cancer
    Anticancer agent 315 is an antitumor agent. Anticancer agent 315 binds to the active pocket of thymidylate synthase via forming strong hydrogen bonds with Lys487 and Ala498, stabilizing the arrangement of the ligand within the pocket. Anticancer agent 315 inhibits the proliferation of tumor cells. Anticancer agent 315 can be used for the research of liver cancer and breast cancer .
    Anticancer agent 315
  • HY-182785
    Photosensitizer-10

    		Photosensitizer Cancer
    Photosensitizer-10 is a glutathione (GSH)-activatable photosensitizer. Photosensitizer-10 shows minimal photoactivity in the absence of glutathione, and generates a highly active species upon reaction with glutathione to induce photo-cytotoxicity. Photosensitizer-10 exhibits selective photo-cytotoxicity toward cancer cells with elevated intracellular glutathione levels while sparing normal cells. Photosensitizer-10 can be used for the research of cancer, such as lung carcinoma and skin carcinoma .
    Photosensitizer-10
  • HY-N18168
    Esculentoside L

    		Others Cancer
    Esculentoside L is a triterpene saponin present in the roots of Phytolacca americana. Esculentoside L increases the intracellular accumulation of calcein in multidrug-resistant human ovarian cancer cells. Esculentoside L exerts no significant cytotoxic activity against non-cancerous cells and hepatocytes. Esculentoside L can be used in studies related to multidrug-resistant human ovarian cancer .
    Esculentoside L
  • HY-181820
    Topoisomerase IV-IN-3

    		Topoisomerase DNA Glycosylase Bacterial Infection
    Topoisomerase IV-IN-3 is a Staphylococcus aureus Topoisomerase IV inhibitor, DNA gyrase inhibitor and antibacterial agent. Topoisomerase IV-IN-3 has IC50 values of 1.32 μM and 0.48 μM against topoisomerase IV, and 0.88 μM and 0.54 μM against DNA gyrase. Topoisomerase IV-IN-3 inhibits decatenation, ATPase, and supercoiling activities of its target enzymes. Topoisomerase IV-IN-3 exerts antibacterial activity against Gram-positive and Gram-negative bacterial strains. Topoisomerase IV-IN-3 exhibits low cytotoxicity toward human fibroblast cells. Topoisomerase IV-IN-3 can be used for the research of bacterial infections .
    Topoisomerase IV-IN-3

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: